Research map: Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy

Back to the article

Papers in this map

  1. Incubation periods of acute respiratory viral infections: a systematic review · Justin Lessler · 2009 · 936 citations · Cited by this paper
  2. Sex‐Related Differences in Physiologically‐Based Biopharmaceutics Modeling · 2026 · Related
  3. Viral Bronchiolitis in Children · H. Cody Meissner · 2016 · 732 citations · Cited by this paper
  4. Follow‐Up Bias in Tumor Dynamic Modeling: A Comparison of Classical and Neural‐ODE Approaches · 2026 · Related
  5. Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study · John P. DeVincenzo · 2014 · 340 citations · Cited by this paper
  6. Evaluating Preclinical‐to‐Human Bioavailability Classification Using Smooth ROC Curve Estimation · 2026 · Related
  7. Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus · John P. DeVincenzo · 2010 · 340 citations · Cited by this paper
  8. Population Pharmacokinetics and Pharmacodynamics of Paracetamol in Malaysian Patients With Plasmodium knowlesi Malaria · 2026 · Related
  9. Respiratory Syncytial Virus Load, Viral Dynamics, and Disease Severity in Previously Healthy Naturally Infected Children · Chadi M. El Saleeby · 2011 · 250 citations · Cited by this paper
  10. Hybrid Systems Modeling of Donor T‐Cell Responses and Graft‐Versus‐Host‐Disease After Posttransplantation Cyclophosphamide Administration · 2026 · Related
  11. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study · John P. DeVincenzo · 2015 · 234 citations · Cited by this paper
  12. Assessing Covariate Clinical Relevance in High‐Dimensional PK Analysis: A Comparison of SCM +, FFEM , and FREM Approaches · 2026 · Related
  13. Viral Shedding and Immune Responses to Respiratory Syncytial Virus Infection in Older Adults · Edward E. Walsh · 2013 · 153 citations · Cited by this paper
  14. Integrative QSP Modeling of Cancer Stem Cells in Triple‐Negative Breast Cancer: Impacts on Tumor Immunity and Response to Immune Checkpoint Inhibitors · 2026 · Related
  15. Respiratory Syncytial Virus Infection in Adults · Ann Regina Falsey · 2007 · 152 citations · Cited by this paper
  16. Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer · 2026 · Related
  17. Plasma Protein Binding of Challenging Compounds · Keith A. Riccardi · 2015 · 119 citations · Cited by this paper
  18. Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling · 2026 · Related
  19. Host Components Contributing to Respiratory Syncytial Virus Pathogenesis · Jonatan J. Carvajal · 2019 · 108 citations · Cited by this paper
  20. Butorphanol Pharmacokinetics Across Species: Meta‐Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling · 2026 · Related
  21. Improving the generation and selection of virtual populations in quantitative systems pharmacology models · Theodore R. Rieger · 2018 · 100 citations · Cited by this paper
  22. COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes · Adrianne L. Jenner · 2021 · 98 citations · Cited by this paper
  23. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein · John P. DeVincenzo · 2019 · 92 citations · Cited by this paper
  24. Viral Load Dynamics and Clinical Disease Severity in Infants With Respiratory Syncytial Virus Infection · Cristina García-Mauriño · 2018 · 89 citations · Cited by this paper
  25. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study · Marita Stevens · 2018 · 88 citations · Cited by this paper
  26. Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein · Zhiwu Sun · 2013 · 85 citations · Cited by this paper
  27. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge · Alaa Ahmad · 2022 · 84 citations · Cited by this paper
  28. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract · Francisco M. Marty · 2019 · 79 citations · Cited by this paper
  29. A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients · Roy F. Chemaly · 2019 · 77 citations · Cited by this paper
  30. Respiratory Syncytial Virus Disease Severity in Young Children · Zaid Haddadin · 2020 · 75 citations · Cited by this paper
  31. Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection · Shunying Zhao · 2024 · 69 citations · Cited by this paper
  32. A comparison of RSV and influenza in vitro kinetic parameters reveals differences in infecting time · Gilberto González‐Parra · 2018 · 50 citations · Cited by this paper
  33. Type III Interferons, Viral Loads, Age, and Disease Severity in Young Children With Respiratory Syncytial Virus Infection · Jeanette Taveras · 2022 · 39 citations · Cited by this paper
  34. Assessing Uncertainty in A2 Respiratory Syncytial Virus Viral Dynamics · Gilberto González‐Parra · 2015 · 36 citations · Cited by this paper
  35. Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results · Abbie Oey · 2023 · 32 citations · Cited by this paper
  36. Risk of Transmission and Viral Shedding From the Time of Infection for Respiratory Syncytial Virus in Households · Hirono Otomaru · 2021 · 31 citations · Cited by this paper
  37. Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants · Monica Brint · 2017 · 30 citations · Cited by this paper
  38. A simple model of COVID-19 explains disease severity and the effect of treatments · Steven Sanche · 2022 · 27 citations · Cited by this paper
  39. A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions · Rohit P. Rao · 2023 · 22 citations · Cited by this paper

Source: OpenAlex (CC0)